Den europeiske union -
italiensk -
EMA (European Medicines Agency)
enrylaze
jazz pharmaceuticals ireland limited - crisantaspase - linfoma di leucemia linfoblastica a cellule precursori - agenti antineoplastici - enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (all) and lymphoblastic lymphoma (lbl) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to e. coli-derived asparaginase.
Den europeiske union -
italiensk -
EMA (European Medicines Agency)
vyxeos liposomal (previously known as vyxeos)
jazz pharmaceuticals ireland limited - daunorubicin hydrochloride, cytarabine - leucemia, mieloide, acuta - agenti antineoplastici - vyxeos liposomiale è indicato per il trattamento di adulti con una diagnosi recente, correlati alla terapia leucemia mieloide acuta (aml-t) o leucemia mieloide acuta con mielodisplasia relative modifiche (aml-mrc).
Italia -
italiensk -
AIFA (Agenzia Italiana del Farmaco)
flukimex
theramex ireland limited - fluconazolo - fluconazolo
Den europeiske union -
italiensk -
EMA (European Medicines Agency)
pylobactell
torbet laboratories ireland limited - urea (13c) - breath tests; helicobacter infections - agenti diagnostici - questo medicinale è solo per uso diagnostico. per la diagnosi in vivo di gastroduodenale da helicobacter pylori (h. pylori) infezione.
Den europeiske union -
italiensk -
EMA (European Medicines Agency)
qaialdo
nova laboratories ireland limited - spironolattone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 e 5.
Sveits -
italiensk -
Swissmedic (Swiss Agency for Therapeutic Products)
euphrasia comp. il collirio
weleda ag - echinacea angustifolia e planta tota rh tm (ph.eur.hom. 1.5.1), euphrasia stricta et euphrasia officinalis e planta tota rh tm (ph.eur.hom. 1.5.1), calendula officinalis e floribus cum calycibus paraffinum liquidum tm (hab 57) - il collirio - echinacea angustifolia e planta tota rh tm (ph.eur.hom. 1.5.1) 30 mg, euphrasia stricta et euphrasia officinalis e planta tota rh tm (ph.eur.hom. 1.5.1) 50 mg, calendula officinalis e floribus cum calycibus paraffinum liquidum tm (hab 57) 50 mg, vaselinum album, paraffinum liquidum, aqua ad iniectabile, cholesterolum, ad unguentum pro 1 g. - zulassung mit reduziertem dossier ohne indikation nach art. 25 abs. 1 kpav (sr 812.212.24) - antroposofici
Sveits -
italiensk -
Swissmedic (Swiss Agency for Therapeutic Products)
vitis comp. compresse masticabili
weleda ag - calcarea formicica (compositio ex: calcium carbonicum hahnemanni (hab) et acidum formicicum (formica animalis totius rec. extracti destillatio (formica rufa l.) d2 (ph.eur.hom. 4.1.1), fragariae vescae folium sicc. (fragaria vesca l., folium), stibium metallicum praeparatum (stibium metallicum hab) d5 (ph.eur.hom. 4.1.1), vitis viniferae folium sicc. (vitis vinifera l., folium) - compresse masticabili - calcarea formicica (compositio ex: calcium carbonicum hahnemanni (hab) et acidum formicicum (formica animalis totius rec. extracti destillatio (formica rufa l.) d2 (ph.eur.hom. 4.1.1) 20 mg, fragariae vescae folium sicc. (fragaria vesca l., folium) 40 mg, stibium metallicum praeparatum (stibium metallicum hab) d5 (ph.eur.hom. 4.1.1) 20 mg, vitis viniferae folium sicc. (vitis vinifera l., folium) 40 mg, lactosum monohydricum, tritici amylum 2.5 mg, calcii behenas, pro compresso 250 mg corresp. lactosum monohydricum 165 mg. - zulassung mit reduziertem dossier ohne indikation nach art. 25 abs. 1 kpav (sr 812.212.24) - antroposofici
Sveits -
italiensk -
Swissmedic (Swiss Agency for Therapeutic Products)
echinaforce hot drink concentrato per la preparazione di una soluzione orale
a.vogel ag - echinaceae purpureae herbae recentis tinctura (echinacea purpurea (l.) moench, herba), echinaceae purpureae radicis recentis tinctura (echinacea purpurea (l.) moench, radix) - concentrato per la preparazione di una soluzione orale - extractum spissum 0.060 g ex echinaceae purpureae herbae recentis tinctura (echinacea purpurea (l.) moench, herba) 1.140 g, ratio: 1:12, auszugsmittel ethanolum 65% (v/v) et echinaceae purpureae radicis recentis tinctura (echinacea purpurea (l.) moench, radix) 0.060 g, ratio: 1:11, auszugsmittel ethanolum 65% (v/v), saccharum 3.222 g, aqua purificata, sambuci fructus succus spissus corresp. saccharum 0.899 g, acidum citricum monohydricum, e 1450 corresp. natrium 0.68 mg, triglycerida media, e 202, ad solutionem pro 5 ml. - bei erkältungskrankheiten und zur vorbeugung bei anfälligkeit gegen erkältungskrankheiten - phytoarzneimittel